Metabolic and Permeation Barriers to the Ocular Absorption of Topically Applied Enkephalins in Albino Rabbits

Vincent H.L. Lee, L. Wulf Carson, Satish Dodda Kashi, Robert Stratford Jr.

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The objective of this study was to test the hypothesis that there existed substantial metabolic and permeation barriers to the ocular absorption of topically applied peptides in the albino rabbit. Leucine enkephalin, methionine enkephalin, and [D-ala2]-met-enkephalinamide were used as model peptides, while radiotracer techniques were used as the analytical methodology. The corneal epithelium was found to offer considerable resistance to the permeation of these peptides from tears into aqueous humor, as evidenced by the 1% or less of topical dose absorbed and by a 14 fold improvement in the amount of peptide absorbed upon removing the corneal epithelium prior to solution instillation. The metabolic barrier, believed to be composed of aminopeptidases and other peptidases, was also substantial in that less than 1% and 13% of the methionine and leucine enkephalins absorbed, respectively, remained intact. Unfortunately, this barrier was not perturbed appreciably by pretreating the eye with bestatin, an aminopeptidase inhibitor. Results obtained with [D-ala2]-metenkephalinamide suggest that a more practical strategy to circumvent this metabolic barrier is to administer metabolically stable peptide analogs.

Original languageEnglish (US)
Pages (from-to)345-352
Number of pages8
JournalJournal of Ocular Pharmacology
Volume2
Issue number4
DOIs
StatePublished - Jan 1 1986
Externally publishedYes

Fingerprint

Enkephalins
Rabbits
Peptides
Leucine Enkephalin
Methionine Enkephalin
Corneal Epithelium
Aminopeptidases
Aqueous Humor
Tears
Peptide Hydrolases
Ocular Absorption

ASJC Scopus subject areas

  • Ophthalmology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Metabolic and Permeation Barriers to the Ocular Absorption of Topically Applied Enkephalins in Albino Rabbits. / Lee, Vincent H.L.; Carson, L. Wulf; Kashi, Satish Dodda; Stratford Jr., Robert.

In: Journal of Ocular Pharmacology, Vol. 2, No. 4, 01.01.1986, p. 345-352.

Research output: Contribution to journalArticle

@article{9d9e813f2a37419f81f41732d113cdd3,
title = "Metabolic and Permeation Barriers to the Ocular Absorption of Topically Applied Enkephalins in Albino Rabbits",
abstract = "The objective of this study was to test the hypothesis that there existed substantial metabolic and permeation barriers to the ocular absorption of topically applied peptides in the albino rabbit. Leucine enkephalin, methionine enkephalin, and [D-ala2]-met-enkephalinamide were used as model peptides, while radiotracer techniques were used as the analytical methodology. The corneal epithelium was found to offer considerable resistance to the permeation of these peptides from tears into aqueous humor, as evidenced by the 1{\%} or less of topical dose absorbed and by a 14 fold improvement in the amount of peptide absorbed upon removing the corneal epithelium prior to solution instillation. The metabolic barrier, believed to be composed of aminopeptidases and other peptidases, was also substantial in that less than 1{\%} and 13{\%} of the methionine and leucine enkephalins absorbed, respectively, remained intact. Unfortunately, this barrier was not perturbed appreciably by pretreating the eye with bestatin, an aminopeptidase inhibitor. Results obtained with [D-ala2]-metenkephalinamide suggest that a more practical strategy to circumvent this metabolic barrier is to administer metabolically stable peptide analogs.",
author = "Lee, {Vincent H.L.} and Carson, {L. Wulf} and Kashi, {Satish Dodda} and {Stratford Jr.}, Robert",
year = "1986",
month = "1",
day = "1",
doi = "10.1089/jop.1986.2.345",
language = "English (US)",
volume = "2",
pages = "345--352",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Metabolic and Permeation Barriers to the Ocular Absorption of Topically Applied Enkephalins in Albino Rabbits

AU - Lee, Vincent H.L.

AU - Carson, L. Wulf

AU - Kashi, Satish Dodda

AU - Stratford Jr., Robert

PY - 1986/1/1

Y1 - 1986/1/1

N2 - The objective of this study was to test the hypothesis that there existed substantial metabolic and permeation barriers to the ocular absorption of topically applied peptides in the albino rabbit. Leucine enkephalin, methionine enkephalin, and [D-ala2]-met-enkephalinamide were used as model peptides, while radiotracer techniques were used as the analytical methodology. The corneal epithelium was found to offer considerable resistance to the permeation of these peptides from tears into aqueous humor, as evidenced by the 1% or less of topical dose absorbed and by a 14 fold improvement in the amount of peptide absorbed upon removing the corneal epithelium prior to solution instillation. The metabolic barrier, believed to be composed of aminopeptidases and other peptidases, was also substantial in that less than 1% and 13% of the methionine and leucine enkephalins absorbed, respectively, remained intact. Unfortunately, this barrier was not perturbed appreciably by pretreating the eye with bestatin, an aminopeptidase inhibitor. Results obtained with [D-ala2]-metenkephalinamide suggest that a more practical strategy to circumvent this metabolic barrier is to administer metabolically stable peptide analogs.

AB - The objective of this study was to test the hypothesis that there existed substantial metabolic and permeation barriers to the ocular absorption of topically applied peptides in the albino rabbit. Leucine enkephalin, methionine enkephalin, and [D-ala2]-met-enkephalinamide were used as model peptides, while radiotracer techniques were used as the analytical methodology. The corneal epithelium was found to offer considerable resistance to the permeation of these peptides from tears into aqueous humor, as evidenced by the 1% or less of topical dose absorbed and by a 14 fold improvement in the amount of peptide absorbed upon removing the corneal epithelium prior to solution instillation. The metabolic barrier, believed to be composed of aminopeptidases and other peptidases, was also substantial in that less than 1% and 13% of the methionine and leucine enkephalins absorbed, respectively, remained intact. Unfortunately, this barrier was not perturbed appreciably by pretreating the eye with bestatin, an aminopeptidase inhibitor. Results obtained with [D-ala2]-metenkephalinamide suggest that a more practical strategy to circumvent this metabolic barrier is to administer metabolically stable peptide analogs.

UR - http://www.scopus.com/inward/record.url?scp=0022913451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022913451&partnerID=8YFLogxK

U2 - 10.1089/jop.1986.2.345

DO - 10.1089/jop.1986.2.345

M3 - Article

C2 - 3503119

AN - SCOPUS:0022913451

VL - 2

SP - 345

EP - 352

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 4

ER -